Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.017%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Mixed End Ahead Of US Fed Interest Rate Decision

Wed, 30th Oct 2019 17:07

(Alliance News) - Stock prices in London closed subdued on Wednesday amid expectations of a further US interest rate cut later in the day, despite the largest economy in the world reporting stronger-than-expected economic growth.

The FTSE 100 index closed up 0.3% at 7,330.78 Wednesday. The mid-cap FTSE 250 index closed down 0.3% at 20,115.10. The AIM All-Share index closed 0.1% lower at 889.80.

The Cboe UK 100 closed up 0.5% at 12,435.12, the Cboe UK 250 down 0.2% at 18,057.91, and the Cboe UK Small Companies down 0.1% at 11,226.09.

The pound was quoted at USD1.2866 at the London close, lower from USD1.2887 late Tuesday.

Data from the US Bureau of Economic Analysis showed that gross domestic product grew 1.9% in the third quarter of 2019 on the year prior. This was slower than the 2.0% reported in the second quarter, but exceeded the 1.7% growth forecast by a FXStreet-compiled consensus.

The bureau explained the pace of growth slowed amid deceleration in personal consumption expenditure and government spending.

"The 1.9% annualised gain in third-quarter GDP, down only marginally from the 2.0% gain in the second, was a little stronger than we had expected," Capital Economics Senior US Economist Andrew Hunter said. "But it still pushed the economy's annual growth rate down to a near three-year low of 2.0% and should be enough to convince Fed officials to deliver another 25 basis points interest rate cut later today."

Later on Wednesday, the US Federal Reserve will announce its interest rate decision at 1800 GMT.

According to the closely-watched CME FedWatch Tool, economists believe there is a 99.5% probability of the Federal Open Market Committee cutting rates to a range of 1.50% to 1.75% from the current 1.75% to 2.00% range with the remainder expecting a cut to between 1.25% and 1.50%.

"The real uncertainty lies in the tone of the post-meeting statement and press conference," Western Asset Portfolio Manager John Bellows said. "We think the Fed will reiterate the dovish arguments that have led to the interest rate cuts this year. That includes an emphasis on 'sustaining the expansion', a discussion of slowing growth, and an admission that inflation is too low."

"These dovish points would come as a surprise to analysts who are expecting a more hawkish message, and certainly would surprise anybody expecting a strong signal from the Fed that it is done cutting," Bellows added.

On Wall Street, the Dow Jones was trading 0.1% higher, the S&P 500 down 0.3%, whilst the Nasdaq was down 0.1%.

In local news, UK Prime Minister Boris Johnson said he is prepared for a "tough" general election battle after members of Parliament cleared the way for the first December poll in almost a century.

Following his Commons victory on Tuesday – at the fourth time of asking – Johnson sought to rally his ruling Conservative MPs ahead of the election on December 12.

The Conservatives go into the campaign in buoyant mood, with one opinion poll at the weekend putting them 16 percentage points ahead of the opposition Labour party.

Amongst the blue chips moving in London, emerging markets-focused lender Standard Chartered closed 2.6% higher after delivering solid third quarter results despite warning of "growing headwinds".

For the three months ended September, pretax profit rose 4% year-on-year to USD1.11 billion, up 16% on an underlying basis. This was after net income climbed 7% to USD3.98 billion amid "broad-based growth" across all business segments and regions.

StanChart warned, however, there are "growing headwinds" such as continued geopolitical tensions as well as an expected slowdown in global economic growth and lower interest rates.

Drugmaker AstraZeneca ended 2.6% higher after it sold the European and Russian commercial rights to schizophrenia and bipolar disorder treatments Seroquel and Seroquel XR to German pharmaceutical firm Cheplapharm Arzneimittel for up to USD239 million.

Both drugs have already lost patent protection in the territories, generating USD108 million in sales in 2018 from those markets.

Fellow pharmaceutical giant GlaxoSmithKline ended 2.4% higher after third quarter profit jumped amid a strong performance in its vaccines unit.

For the three months ended September, pretax profit rose 14% on the year to GBP1.95 billion after revenue rose 16% to GBP9.39 billion.

Revenue performance was particularly helped by strong 20% Vaccines growth, courtesy of higher sales of its shingles vaccine Shingrix, as well as meningitis and flu vaccine contributions.

In the red amongst the blue chips, clothing and homewares retailer Next ended 2.9% lower despite reporting third-quarter full price sales were slightly ahead of guidance and it held its full year outlook.

For the quarter ended October 26, total full price sales were up 2.0% which was "slightly ahead" of guidance given in September.

Retail sales, however, were down 6.3% whilst online sales grew 9.7% and finance interest income up 7.0%. In the year to October 26, total full price sales were up 3.5%.

The UK retail bellwether said it thinks strong sales in July pulled forward sales from August, while sales in September were "adversely affected by unusually warm weather". This was followed by a "significant improvement" in October when temperatures fell and the heavens opened with rain.

In the FTSE 250, ConvaTec Group jumped 11% after the medical devices maker hailed a "solid" third quarter and it held firm to full year guidance.

For the three months ended September, revenue grew 2.4% on the year prior to USD462.9 million with organic growth up 4.6%. Group performance was boosted by growth in all of the company's units - Advanced Wound Care, Ostomy Care, Continence & Critical Care, and Infusion Devices.

The company also said its outlook for 2019 is unchanged, still guiding for organic revenue growth of between 1.0% to 2.5%.

Elsewhere in London, Applied Graphene finished 9.1% higher after it launched a graphene anti-corrosion paint primer into the UK mainstream market through car and cycling products retailer Halfords Group.

Applied Graphene Chief Executive Officer Adrian Potts described the deal as a "landmark moment" for the firm and its products.

Security and surveillance firm Synectics closed 18% lower after it reported its full year results are expected to be "materially" below market expectations amid "difficult" UK market conditions.

In mainland Europe, in Paris the CAC 40 equities index ended up 0.2%, while the DAX 30 in Frankfurt ended down 0.3%.

The euro was quoted at USD1.1122, higher compared to USD1.1108 late Tuesday. The dollar was trading at JPY108.87, broadly unchanged compared to JPY108.91 late Tuesday.

Gold was quoted at USD1,493.92 an ounce at the London equities close, higher versus USD1,488.37 Tuesday.

Brent oil was quoted at USD60.91 a barrel at the London equities close, lower than USD61.86 at the close Tuesday.

In the economic calendar on Thursday, there is China prints purchasing managers index data at 0100 GMT.

The Bank of Japan delivers its interest rate decision ahead of a press conference at 0600 GMT. Japan will also release consumer confidence figures at 0500 GMT.

In Europe, German retail sales figures are released at 0700 GMT with eurozone GDP, CPI and unemployment rate data delivered at 1000 GMT.

In the US, jobless claims figures are printed at 1230 GMT ahead of Chicago PMI at 1345 GMT.

In UK corporate events on Monday, third quarter results are due from oil major Royal Dutch Shell, lender Lloyds Banking Group, British Airways-owner International Consolidated Airlines, drugsmaker Indivior, medical devices maker Smith & Nephew and chemicals firm Elementis. Interim results will come from telecommunications firm BT Group.

By Ahren Lester; ahrenlester@alliancenews.com

London Close is available to subscribers as an email newsletter. Contact info@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
5 Apr 2024 07:23

AstraZeneca announces positive lung cancer treatment trial results

(Sharecast News) - AstraZeneca announced positive high-level results from a phase three trial demonstrating significant advancements in the treatment of limited-stage small cell lung cancer (LS-SCLC) on Friday.

Read more
4 Apr 2024 13:09

UK shareholder meetings calendar - next 7 days

Friday 5 April 
Faron Pharmaceuticals LtdAGM
VPC Specialty Lending Investments PLCGM re capital return via B share scheme
Monday 8 April 
Premier African Minerals LtdAGM
Tuesday 9 April 
Ethernity Networks LtdEGM re board appointments and option grants
Wednesday 10 April 
Valereum PLCAGM
Wincanton PLCGM re takeover by GXO Logistics Inc
Thursday 11 April 
AstraZeneca PLCAGM
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 17:22

UK's FTSE 100 pressured by stronger pound; miners climb

FTSE 100 flat, FTSE 250 up 0.2%

*

Read more
3 Apr 2024 11:02

CORRECT: AstraZeneca, Daiichi make US progress with licence approvals

(Correcting the description of extravascular haemolysis' effects on patients with paroxysmal nocturnal haemoglobinuria)

Read more
2 Apr 2024 15:22

London close: Stocks turn red on return from Easter break

(Sharecast News) - UK stocks experienced a downturn by the end of trading on Tuesday, as investors resumed activity following the extended weekend, with initial gains reversed by the close ahead of a week marked by a number of key economic data releases.

Read more
2 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 buoyed by UK manufacturing growth

(Alliance News) - The FTSE 100 in London was up at midday on Tuesday, reacting to the UK manufacturing sector returning growth and further PMI data across the globe.

Read more
2 Apr 2024 10:25

AstraZeneca and Daiichi make US progress with latest licence approvals

(Alliance News) - AstraZeneca PLC on Tuesday noted significant progress for two of its clinical-stage treatments in the US.

Read more
2 Apr 2024 09:54

LONDON BROKER RATINGS: Bernstein starts AstraZeneca at 'outperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
2 Apr 2024 09:09

LONDON MARKET OPEN: FTSE 100 up as oil majors and gold miners shine

(Alliance News) - Stock prices in London opened higher on Tuesday, in confident trade following the long Easter weekend, ahead of a UK manufacturing sector reading later in the morning.

Read more
2 Apr 2024 08:05

LONDON BRIEFING: HSBC in special payout on Canada sale; Astra FDA win

(Alliance News) - London's FTSE 100 traded higher on Tuesday following the long weekend, as investors react to US data, and look ahead to manufacturing sector readings from Europe later.

Read more
2 Apr 2024 07:08

US FDA gives green light for use of AstraZeneca's Voydeva

(Sharecast News) - America's drug regulator gave the green light to AstraZeneca's for the add-on use of Voydeya in the treatment of extravascular haemolysis (EVH) in patients with paroxysmal nocturnal haemoglobinuria (PNH).

Read more
27 Mar 2024 12:02

LONDON MARKET MIDDAY: FTSE 100 underperforms ahead of US PCE data

(Alliance News) - Stock prices in London were lower at midday on Wednesday, but trade was more confident in mainland Europe, with focus turning to the release of the US Federal Reserve's preferred inflation gauge on Friday.

Read more
27 Mar 2024 11:56

C4X Discovery seeks AIM delisting but half-year revenue skyrockets

(Alliance News) - C4X Discovery Holdings PLC shares plunged on Wednesday after it said it plans to delist from AIM in London, due to "the recent downturn in the financial markets" hampering its valuation.

Read more
27 Mar 2024 09:19

AstraZeneca treatments become "first and only" to be approved in Japan

(Alliance News) - AstraZeneca PLC announced on Wednesday the approval of two of its treatments for use in Japan.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.